{"qas": [{"question": "NICE decides the availability of drugs in which two countries?", "id": "571d2c3b5efbb31900334ec2", "answers": [{"text": "England and Wales", "answer_start": 263}], "is_impossible": false}, {"question": "What is the name of the organization in Scotland that decides the availability of drugs?", "id": "571d2c3b5efbb31900334ec3", "answers": [{"text": "Scottish Medicines Consortium", "answer_start": 429}], "is_impossible": false}, {"question": "What threshold must a drug pass before it is approved?", "id": "571d2c3b5efbb31900334ec4", "answers": [{"text": "cost-effectiveness", "answer_start": 575}], "is_impossible": false}, {"plausible_answers": [{"text": "England and Wales", "answer_start": 263}], "question": "QALY decides the availability of drugs in which two countries?", "id": "5ad3a314604f3c001a3fea45", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "Scottish Medicines Consortium", "answer_start": 429}], "question": "What is the name of the organization in Wales that decides the availability of drugs?", "id": "5ad3a314604f3c001a3fea46", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "cost-effectiveness", "answer_start": 575}], "question": "What threshold must a Wales pass before it is approved?", "id": "5ad3a314604f3c001a3fea47", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "England and Wales", "answer_start": 263}], "question": "Where does QALY decide whether decide in what circumstances drugs and technologies will be made available?", "id": "5ad3a314604f3c001a3fea48", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "pass the threshold for cost-effectiveness", "answer_start": 552}], "question": "What must the NHS do in order to be approved?", "id": "5ad3a314604f3c001a3fea49", "answers": [], "is_impossible": true}], "context": "In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In <a0_0><b3_0><b6_0>England and Wales<b6_0/><b3_0/><a0_0/> NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the <a1_0><b4_0>Scottish Medicines Consortium<b4_0/><a1_0/> in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. A product must <b7_0>pass the threshold for <a2_0><b5_0>cost-effectiveness<b7_0/><b5_0/><a2_0/> if it is to be approved. Treatments must represent 'value for money' and a net benefit to society."}